NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Trial Parameters
Brief Summary
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1. * Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma. * Have metastatic disease * Must not have received prior systemic treatment for pancreatic cancer. * Have measurable disease based on RECIST 1.1. * Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures. * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. * For both Women and Men, must use acceptable form of birth control while on study. * Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and institutional guidelines. Exclusion Criteria: * Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses. * Has received radiotherapy